AML MRD Detection Assay
Next-generation sequencing (NGS) is a powerful emerging method for detecting residual acute myeloid leukemia (AML) after treatment. However, current methods produce an abundance of sequencing errors which obscure low-frequency leukemia-defining mutations.
The TwinStrand Duplex Sequencing™ AML MRD assay is orders of magnitude more sensitive and specific than other NGS-based MRD assays, offering unprecedented opportunities for clinical research and drug development.
- >100-fold higher resolution than other error-corrected NGS methods
- The 29 gene, 58kb panel encompasses loci mutated in 90%-95% of adult AML patients
- Assay enables sub-1/10,000 limit of detection anywhere in target region